
Feature|Videos|May 28, 2024
A Different CDMO Experience: Q&A With Scorpius’ President & COO Joe Payne
Author(s)Scorpius BioManufacturing
Joe Payne, Scorpius BioManufacturing, comments on the unique needs of today's biopharmaceutical companies looking to develop and manufacture small-volume, early-stage large molecules.
Watch the video and learn more:
- Learn about Scorpius’ president and COO, Joe Payne, as a thought leader who is also approachable, energetic, and in-tune with client needs.
- Learn about Scorpius’ competitive advantages in biomanufacturing of small-volume, early-stage large molecules.
- Learn what it takes to produce an end product that can be shared with both prospective clients and prospective employees.
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
Trending on Pharmaceutical Technology
1
FAQ: FDA’s Shifts in Pharma Regulation and Strategy in 2025
2
EMA Calls New EU Pharma Legislation Most Significant in Two Decades
3
FDA’s CNPV Pilot Gives First Approval to Antibiotic for Pneumonia and Sinusitis
4
PharmTech Weekly News Roundup – Week of December 8, 2025
5


![[Rishi Pimentel, gChem]](https://cdn.sanity.io/images/0vv8moc6/pharmtech/16bc98940a34f0991f9ca5e7ccbfa6889fec078f-1634x909.jpg?w=350&fit=crop&auto=format)
![[Rishi Pimentel, gChem]](https://cdn.sanity.io/images/0vv8moc6/pharmtech/01d391920288b8bd8b751988988b5a6544a6ddaa-1629x908.jpg?w=350&fit=crop&auto=format)
![[Nigel Langley]](https://cdn.sanity.io/images/0vv8moc6/pharmtech/e2c0137d8224aaa1f14c0f1af43b58d21f4541dd-1768x904.jpg?w=350&fit=crop&auto=format)
